Vaccines -

The Vaccinated Are Now Patented Property, Says The Supreme Court

Are You On Somebody’s Patent List?

The text below is from the Supreme Court that says, you CANNOT patent DNA! But, those who get vaccinated have their DNA turned into something patentable…the Supreme Court ruled that if a human genome is modified by mRNA vaccines (which are currently in use), then the genome can be patented. Is this how they decided to execute their plan of depopulation by vaccine. You can download the PDF, a good idea, so you’ll have this information.

They forget to mention that the Covid Vaccine has killed as much as 50,000 people.

You can read the original by Debra Heine here.

I broke the text into smaller paragraphs to make it easier to read. If you want to have it in its original form, click the link below to get the PDF.

If you get vaccinated with mRNA vaccines, your genome can be patented.

The MARXIST regime currently installed in the White House is a THREAT to the freedom of The United States. DO NOT GET VACCINATED, we can no longer put up with this subversion!

There were about 6,000,000 other people who had NUMBERS written on them as well…what happened to them?

Supreme Court Ruling

OCTOBER TERM, 2012
Syllabus NOTE: Where it is feasible, a syllabus (headnote) will be released, as is being done in connection with this case, at the time the opinion is issued. The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See United States v. Detroit Timber & Lumber Co., 200 U. S. 321, 337.

SUPREME COURT OF THE UNITED STATES
Syllabus ASSOCIATION FOR MOLECULAR PATHOLOGY ET AL. v. MYRIAD GENETICS, INC., ET AL. CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT No. 12–398. Argued April 15, 2013—Decided June 13, 2013 Each human gene is encoded as deoxyribonucleic acid (DNA), which takes the shape of a “double helix.”

Each “cross-bar” in that helix consists of two chemically joined nucleotides. Sequences of DNA nu- cleotides contain the information necessary to create strings of amino acids used to build proteins in the body. The nucleotides that code for amino acids are “exons,” and those that do not are “introns.”

Sci- entists can extract DNA from cells to isolate specific segments for study. They can also synthetically create exons-only strands of nu- cleotides known as complementary DNA (cDNA). cDNA contains only the exons that occur in DNA, omitting the intervening introns. Respondent Myriad Genetics, Inc. (Myriad), obtained several pa- tents after discovering the precise location and sequence of the BRCA1 and BRCA2 genes, mutations of which can dramatically in- crease the risk of breast and ovarian cancer.

This knowledge allowed Myriad to determine the genes’ typical nucleotide sequence, which, in turn, enabled it to develop medical tests useful for detecting muta- tions in these genes in a particular patient to assess the patient’s cancer risk.

If valid, Myriad’s patents would give it the exclusive right to isolate an individual’s BRCA1 and BRCA2 genes, and would give Myriad the exclusive right to synthetically create BRCA cDNA. Petitioners filed suit, seeking a declaration that Myriad’s patents are invalid under 35 U. S. C. §101.

As relevant here, the District Court granted summary judgment to petitioners, concluding that Myriad’s claims were invalid because they covered products of nature. The Federal Circuit initially reversed, but on remand in light of Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U. S. _, the Circuit found both isolated DNA and cDNA patent eligible.

2 ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.

Syllabus
Held: A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring. Pp. 10–18. (a) The Patent Act permits patents to be issued to “[w]hoever in- vents or discovers any new and useful . . . composition of matter,” §101, but “laws of nature, natural phenomena, and abstract ideas” “ ‘are basic tools of scientific and technological work’ ” that lie beyond the domain of patent protection, Mayo, supra, at .

The rule against patents on naturally occurring things has limits, however. Patent protection strikes a delicate balance between creating “incen- tives that lead to creation, invention, and discovery” and “imped[ing] the flow of information that might permit, indeed spur, invention.” Id., at .

This standard is used to determine whether Myriad’s pa- tents claim a “new and useful . . . composition of matter,” §101, or claim naturally occurring phenomena. Pp. 10–11. (b) Myriad’s DNA claim falls within the law of nature exception. Myriad’s principal contribution was uncovering the precise location and genetic sequence of the BRCA1 and BRCA2 genes.

Diamond v. Chakrabarty, 447 U. S. 303, is central to the patent-eligibility inquiry whether such action was new “with markedly different characteris- tics from any found in nature,” id., at 310. Myriad did not create or alter either the genetic information encoded in the BCRA1 and BCRA2 genes or the genetic structure of the DNA.

It found an im- portant and useful gene, but groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry. See Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U. S. 127. Finding the location of the BRCA1 and BRCA2 genes does not render the genes patent eligible “new . . . composition[s] of matter,” §101. Myri- ad’s patent descriptions highlight the problem with its claims:

They detail the extensive process of discovery, but extensive effort alone is insufficient to satisfy §101’s demands. Myriad’s claims are not saved by the fact that isolating DNA from the human genome severs the chemical bonds that bind gene molecules together.

The claims are not expressed in terms of chemical composition, nor do they rely on the chemical changes resulting from the isolation of a particular DNA section. Instead, they focus on the genetic information encoded in the BRCA1 and BRCA2 genes.

Finally, Myriad argues that the Patent and Trademark Office’s past practice of awarding gene patents is en- titled to deference, citing J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred Int’l, Inc., 534 U. S. 124, a case where Congress had endorsed a PTO practice in subsequent legislation. There has been no such endorse- ment here, and the United States argued in the Federal Circuit and in this Court that isolated DNA was not patent eligible under §101. Pp. 12–16.

Cite as: 569 U. S. __ (2013) 3
Syllabus (c) cDNA is not a “product of nature,” so it is patent eligible under §101. cDNA does not present the same obstacles to patentability as naturally occurring, isolated DNA segments. Its creation results in an exons-only molecule, which is not naturally occurring.

Its order of the exons may be dictated by nature, but the lab technician unques- tionably creates something new when introns are removed from a DNA sequence to make cDNA. Pp. 16–17. (d) This case, it is important to note, does not involve method claims, patents on new applications of knowledge about the BRCA1 and BRCA2 genes, or the patentability of DNA in which the order of the naturally occurring nucleotides has been altered. Pp. 17–18. 689 F. 3d 1303, affirmed in part and reversed in part.

THOMAS, J., delivered the opinion of the Court, in which ROBERTS, C. J., and KENNEDY, GINSBURG, BREYER, ALITO, SOTOMAYOR, and KAGAN, JJ., joined, and in which SCALIA, J., joined in part. SCALIA, J., filed an opinion concurring in part and concurring in the judgment.

Cite as: 569 U. S. __ (2013) 1
Opinion of the Court NOTICE: This opinion is subject to formal revision before publication in the preliminary print of the United States Reports. Readers are requested to notify the Reporter of Decisions, Supreme Court of the United States, Wash- ington, D. C. 20543, of any typographical or other formal errors, in order that corrections may be made before the preliminary print goes to press.

SUPREME COURT OF THE UNITED STATES
No. 12–398
ASSOCIATION FOR MOLECULAR PATHOLOGY,
ET AL., PETITIONERS v. MYRIAD
GENETICS, INC., ET AL.
ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF
APPEALS FOR THE FEDERAL CIRCUIT
[June 13, 2013]
JUSTICE THOMAS delivered the opinion of the Court. Respondent Myriad Genetics, Inc. (Myriad), discovered the precise location and sequence of two human genes, mutations of which can substantially increase the risks of breast and ovarian cancer. Myriad obtained a number of patents based upon its discovery.

This case involves claims from three of them and requires us to resolve whether a naturally occurring segment of deoxyribonucleic acid (DNA) is patent eligible under 35 U. S. C. §101 by virtue of its isolation from the rest of the human genome.

We also address the patent eligibility of synthetically created DNA known as complementary DNA (cDNA), which contains the same protein-coding information found in a segment of natural DNA but omits portions within the DNA segment that do not code for proteins.

For the rea- sons that follow, we hold that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but that cDNA is patent eligible because it is not naturally occurring. We, therefore, affirm in part and reverse in part the decision of

2 ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.

Opinion of the Court
the United States Court of Appeals for the Federal Circuit. I
A
Genes form the basis for hereditary traits in living organisms. See generally Association for Molecular Pa- thology v. United States Patent and Trademark Office, 702 F. Supp. 2d 181, 192–211 (SDNY 2010). The human ge- nome consists of approximately 22,000 genes packed into 23 pairs of chromosomes. Each gene is encoded as DNA, which takes the shape of the familiar “double helix” that Doctors James Watson and Francis Crick first de- scribed in 1953. Each “cross-bar” in the DNA helix con- sists of two chemically joined nucleotides.

The possible nucleotides are adenine (A), thymine (T), cytosine (C), and guanine (G), each of which binds naturally with another nucleotide: A pairs with T; C pairs with G. The nucleotide cross-bars are chemically connected to a sugar-phosphate backbone that forms the outside framework of the DNA helix. Sequences of DNA nucleotides contain the infor- mation necessary to create strings of amino acids, which in turn are used in the body to build proteins.

Only some DNA nucleotides, however, code for amino acids; these nucleotides are known as “exons.” Nucleotides that do not code for amino acids, in contrast, are known as “introns.” Creation of proteins from DNA involves two principal steps, known as transcription and translation. In tran- scription, the bonds between DNA nucleotides separate, and the DNA helix unwinds into two single strands.

A single strand is used as a template to create a complemen- tary ribonucleic acid (RNA) strand. The nucleotides on the DNA strand pair naturally with their counterparts, with the exception that RNA uses the nucleotide base uracil (U) instead of thymine (T). Transcription results in a single strand RNA molecule, known as pre-RNA, whose nucleo- tides form an inverse image of the DNA strand from which

Cite as: 569 U. S. __ (2013) 3
Opinion of the Court it was created. Pre-RNA still contains nucleotides corre- sponding to both the exons and introns in the DNA mole- cule. The pre-RNA is then naturally “spliced” by the physical removal of the introns. The resulting product is a strand of RNA that contains nucleotides corresponding only to the exons from the original DNA strand.

The exons-only strand is known as messenger RNA (mRNA), which creates amino acids through translation. In trans- lation, cellular structures known as ribosomes read each set of three nucleotides, known as codons, in the mRNA. Each codon either tells the ribosomes which of the 20 possible amino acids to synthesize or provides a stop signal that ends amino acid production. DNA’s informational sequences and the processes that create mRNA, amino acids, and proteins occur naturally within cells.

Scientists can, however, extract DNA from cells using well known laboratory methods. These meth- ods allow scientists to isolate specific segments of DNA— for instance, a particular gene or part of a gene—which can then be further studied, manipulated, or used.

It is also possible to create DNA synthetically through processes similarly well known in the field of genetics. One such method begins with an mRNA molecule and uses the natural bonding properties of nucleotides to create a new, synthetic DNA molecule. The result is the inverse of the mRNA’s inverse image of the original DNA, with one important distinction: Because the natural creation of mRNA involves splicing that removes introns, the synthetic DNA created from mRNA also contains only the exon sequences.

This synthetic DNA created in the laboratory from mRNA is known as complementary DNA (cDNA). Changes in the genetic sequence are called mutations. Mutations can be as small as the alteration of a single nucleotide—a change affecting only one letter in the genetic code. Such small-scale changes can produce an entirely different amino acid or can end protein production alto-

4 ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.

Opinion of the Court
gether. Large changes, involving the deletion, rearrange- ment, or duplication of hundreds or even millions of nu- cleotides, can result in the elimination, misplacement, or duplication of entire genes. Some mutations are harmless, but others can cause disease or increase the risk of dis- ease. As a result, the study of genetics can lead to valu- able medical breakthroughs.

B This case involves patents filed by Myriad after it made one such medical breakthrough. Myriad discovered the precise location and sequence of what are now known as the BRCA1 and BRCA2 genes. Mutations in these genes can dramatically increase an individual’s risk of develop- ing breast and ovarian cancer.

The average American woman has a 12- to 13-percent risk of developing breast cancer, but for women with certain genetic mutations, the risk can range between 50 and 80 percent for breast can- cer and between 20 and 50 percent for ovarian cancer. Before Myriad’s discovery of the BRCA1 and BRCA2 genes, scientists knew that heredity played a role in estab- lishing a woman’s risk of developing breast and ovarian cancer, but they did not know which genes were associated with those cancers.

Myriad identified the exact location of the BRCA1 and BRCA2 genes on chromosomes 17 and 13. Chromosome 17 has approximately 80 million nucleotides, and chro- mosome 13 has approximately 114 million. Association for Molecular Pathology v. United States Patent and Trade- mark Office, 689 F. 3d 1303, 1328 (CA Fed. 2012).

Within those chromosomes, the BRCA1 and BRCA2 genes are each about 80,000 nucleotides long. If just exons are counted, the BRCA1 gene is only about 5,500 nucleotides long; for the BRCA2 gene, that number is about 10,200. Ibid. Knowledge of the location of the BRCA1 and BRCA2 genes allowed Myriad to determine their typical nucleotide

Cite as: 569 U. S. __ (2013) 5
Opinion of the Court sequence.1 That information, in turn, enabled Myriad to develop medical tests that are useful for detecting muta- tions in a patient’s BRCA1 and BRCA2 genes and thereby assessing whether the patient has an increased risk of cancer.

Once it found the location and sequence of the BRCA1 and BRCA2 genes, Myriad sought and obtained a number of patents. Nine composition claims from three of those patents are at issue in this case.2 See id., at 1309, and n. 1 (noting composition claims). Claims 1, 2, 5, and 6 from the ’282 patent are representative.

The first claim asserts a patent on “[a]n isolated DNA coding for a BRCA1 polypeptide,” which has “the amino acid sequence set forth in SEQ ID NO:2.” App. 822. SEQ ID NO:2 sets forth a list of 1,863 amino acids that the typical BRCA1 gene encodes. See id., at 785–790. Put differently, claim 1 asserts a patent claim on the DNA code that tells a cell to produce the string of BRCA1 amino acids listed in SEQ ID NO:2. Claim 2 of the ’282 patent operates similarly.

It claims “[t]he isolated DNA of claim 1, wherein said DNA has the nucleotide sequence set forth in SEQ ID NO:1.” Id., at 822. Like SEQ ID NO:2, SEQ ID NO:1 sets forth a long list of data, in this instance the sequence of cDNA that codes for the BRCA1 amino acids listed in claim 1. Im- portantly, SEQ ID NO:1 lists only the cDNA exons in the BRCA1 gene, rather than a full DNA sequence contain- ing both exons and introns.

See id., at 779 (stating that SEQ ID NO:1’s “MOLECULE TYPE:” is “cDNA”). As a re- sult, the Federal Circuit recognized that claim 2 asserts a patent on the cDNA nucleotide sequence listed in SEQ ID —————— 1Technically, there is no “typical” gene because nucleotide sequences vary between individuals, sometimes dramatically.

Geneticists refer to the most common variations of genes as “wild types.” 2At issue are claims 1, 2, 5, 6, and 7 of U. S. Patent 5,747,282 (the ’282 patent), claim 1 of U. S. Patent 5,693,473 (the ’473 patent), and claims 1, 6, and 7 of U. S. Patent 5,837,492 (the ’492 patent).

6 ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.

Opinion of the Court
NO:1, which codes for the typical BRCA1 gene. 689 F. 3d, at 1326, n. 9; id., at 1337 (Moore, J., concurring in part); id., at 1356 (Bryson, J., concurring in part and dissenting in part). Claim 5 of the ’282 patent claims a subset of the data in claim 1. In particular, it claims “[a]n isolated DNA having at least 15 nucleotides of the DNA of claim 1.” App. 822.

The practical effect of claim 5 is to assert a patent on any series of 15 nucleotides that exist in the typical BRCA1 gene. Because the BRCA1 gene is thousands of nucleo- tides long, even BRCA1 genes with substantial mutations are likely to contain at least one segment of 15 nucleotides that correspond to the typical BRCA1 gene.

Similarly, claim 6 of the ’282 patent claims “[a]n isolated DNA hav- ing at least 15 nucleotides of the DNA of claim 2.” Ibid. This claim operates similarly to claim 5, except that it references the cDNA-based claim 2. The remaining claims at issue are similar, though several list common mutations rather than typical BRCA1 and BRCA2 sequences.

See ibid. (claim 7 of the ’282 patent); id., at 930 (claim 1 of the ’473 patent); id., at 1028 (claims 1, 6, and 7 of the ’492 patent). C Myriad’s patents would, if valid, give it the exclusive right to isolate an individual’s BRCA1 and BRCA2 genes (or any strand of 15 or more nucleotides within the genes) by breaking the covalent bonds that connect the DNA to the rest of the individual’s genome.

The patents would also give Myriad the exclusive right to synthetically create BRCA cDNA. In Myriad’s view, manipulating BRCA DNA in either of these fashions triggers its “right to exclude others from making” its patented composition of matter under the Patent Act. 35 U. S. C. §154(a)(1); see also §271(a) (“[W]hoever without authority makes . . . any patented invention . . . infringes the patent”).

Cite as: 569 U. S. __ (2013) 7
Opinion of the Court But isolation is necessary to conduct genetic testing, and Myriad was not the only entity to offer BRCA testing after it discovered the genes. The University of Pennsylvania’s Genetic Diagnostic Laboratory (GDL) and others provided genetic testing services to women.

Petitioner Dr. Harry Ostrer, then a researcher at New York University School of Medicine, routinely sent his patients’ DNA samples to GDL for testing. After learning of GDL’s testing and Ostrer’s activities, Myriad sent letters to them asserting that the genetic testing infringed Myriad’s patents. App. 94–95 (Ostrer letter). In response, GDL agreed to stop testing and informed Ostrer that it would no longer accept patient samples.

Myriad also filed patent infringement suits against other entities that performed BRCA testing, resulting in settlements in which the defendants agreed to cease all allegedly infringing activity. 689 F. 3d, at 1315. Myriad, thus, solidified its position as the only entity providing BRCA testing.

Some years later, petitioner Ostrer, along with medical patients, advocacy groups, and other doctors, filed this lawsuit seeking a declaration that Myriad’s patents are invalid under 35 U. S. C. §101. 702 F. Supp. 2d, at 186.

Citing this Court’s decision in MedImmune, Inc. v. Genen- tech, Inc., 549 U. S. 118 (2007), the District Court denied Myriad’s motion to dismiss for lack of standing. Associa- tion for Molecular Pathology v. United States Patent and Trademark Office, 669 F. Supp. 2d 365, 385–392 (SDNY 2009).

The District Court then granted summary judg- ment to petitioners on the composition claims at issue in this case based on its conclusion that Myriad’s claims, including claims related to cDNA, were invalid because they covered products of nature. 702 F. Supp. 2d, at 220– 237. The Federal Circuit reversed, Association for Molecu- lar Pathology v. United States Patent and Trademark Office, 653 F. 3d 1329 (2011), and this Court granted the petition for certiorari, vacated the judgment, and

8 ASSOCIATION FOR MOLECULAR PATHOLOGY v.
MYRIAD GENETICS, INC.

Opinion of the Court
remanded the case in light of Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U. S. _ (2012). See Association for Molecular Pathology v. Myriad Genet- ics, Inc., 566 U. S. _ (2012). On remand, the Federal Circuit affirmed the District Court in part and reversed in part, with each member of the panel writing separately.

All three judges agreed that only petitioner Ostrer had standing. They reasoned that Myriad’s actions against him and his stated ability and willingness to begin BRCA1 and BRCA2 testing if Myr- iad’s patents were invalidated were sufficient for Article III standing. 689 F. 3d, at 1323; id., at 1337 (opinion of Moore, J.); id., at 1348 (opinion of Bryson, J.).

With respect to the merits, the court held that both isolated DNA and cDNA were patent eligible under §101. The central dispute among the panel members was whether the act of isolating DNA—separating a specific gene or sequence of nucleotides from the rest of the chromosome—is an inventive act that entitles the individ- ual who first isolates it to a patent.

Each of the judges on the panel had a different view on that question. Judges Lourie and Moore agreed that Myriad’s claims were patent eligible under §101 but disagreed on the rationale. Judge Lourie relied on the fact that the entire DNA molecule is held together by chemical bonds and that the covalent bonds at both ends of the segment must be severed in order to isolate segments of DNA.

This process technically creates new molecules with unique chemical compositions. See id., at 1328 (“Isolated DNA . . . is a free-standing portion of a larger, natural DNA molecule. Isolated DNA has been cleaved (i.e., had covalent bonds in its backbone chemically severed) or synthesized to consist of just a fraction of a naturally occurring DNA molecule”). Judge Lourie found this chemical alteration to be dispositive, because isolating a particular strand of DNA creates a nonnaturally occurring molecule, even though the

Cite as: 569 U. S. __ (2013) 9
Opinion of the Court chemical alteration does not change the information- transmitting quality of the DNA. See id., at 1330 (“The claimed isolated DNA molecules are distinct from their natural existence as portions of larger entities, and their informational content is irrelevant to that fact.

We recog- nize that biologists may think of molecules in terms of their uses, but genes are in fact materials having a chemi- cal nature”). Accordingly, he rejected petitioners’ argument that isolated DNA was ineligible for patent protection as a product of nature. Judge Moore concurred in part but did not rely exclu- sively on Judge Lourie’s conclusion that chemically break- ing covalent bonds was sufficient to render isolated DNA patent eligible.

Id., at 1341 (“To the extent the majority rests its conclusion on the chemical differences between [naturally occurring] and isolated DNA (breaking the covalent bonds), I cannot agree that this is sufficient to hold that the claims to human genes are directed to pa- tentable subject matter”).

Instead, Judge Moore also relied on the United States Patent and Trademark Office’s (PTO) practice of granting such patents and on the reli- ance interests of patent holders. Id., at 1343. However, she acknowledged that her vote might have come out differently if she “were deciding this case on a blank can- vas.” Ibid. Finally, Judge Bryson concurred in part and dissented in part, concluding that isolated DNA is not patent eli- gible.

As an initial matter, he emphasized that the break- ing of chemical bonds was not dispositive: “[T]here is no magic to a chemical bond that requires us to recognize a new prod- uct when a chemical bond is created or broken.” Id., at 1351. Instead, he relied on the fact that “[t]he nucleo- tide sequences of the claimed molecules are the same as the nucleotide sequences found in naturally occurring human genes.” Id., at 1355. Judge Bryson then concluded that genetic “structural similarity dwarfs the significance

10 ASSOCIATION FOR MOLECULAR PATHOLOGY v.
MYRIAD GENETICS, INC.

Opinion of the Court
of the structural differences between isolated DNA and naturally occurring DNA, especially where the structural differences are merely ancillary to the breaking of covalent bonds, a process that is itself not inventive.” Ibid. More- over, Judge Bryson gave no weight to the PTO’s position on patentability because of the Federal Circuit’s position that “the PTO lacks substantive rulemaking authority as to issues such as patentability.” Id., at 1357.

Although the judges expressed different views concern- ing the patentability of isolated DNA, all three agreed that patent claims relating to cDNA met the patent eligibility requirements of §101. Id., at 1326, and n. 9 (recognizing that some patent claims are limited to cDNA and that such claims are patent eligible under §101); id., at 1337 (Moore, J., concurring in part); id., at 1356 (Bryson, J., concurring in part and dissenting in part) (“cDNA cannot be isolated from nature, but instead must be created in the laboratory . . . because the introns that are found in the native gene are removed from the cDNA segment”).3 We granted certiorari. 568 U. S. _ (2012). II

A
Section 101 of the Patent Act provides: “Whoever invents or discovers any new and useful . . . composition of matter, or any new and useful im- provement thereof, may obtain a patent therefor, sub- ject to the conditions and requirements of this title.” —————— 3Myriad continues to challenge Dr. Ostrer’s Declaratory Judgment Act standing in this Court.

Brief for Respondents 17–22. But we find that, under the Court’s decision in MedImmune, Inc. v. Genentech, Inc., Dr. Ostrer has alleged sufficient facts “under all the circumstances, [to] show that there is a substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance of a declaratory judgment.” 549 U. S. 118, 127 (2007) (internal quotation marks omitted).

Cite as: 569 U. S. _ (2013) 11 Opinion of the Court 35 U. S. C. §101. We have “long held that this provision contains an im- portant implicit exception[:] Laws of nature, natural phe- nomena, and abstract ideas are not patentable.” Mayo, 566 U. S., at (slip op., at 1) (internal quotation marks and brackets omitted).

Rather, “‘they are the basic tools of scientific and technological work’” that lie beyond the domain of patent protection. Id., at _ (slip op., at 2). As the Court has explained, without this exception, there would be considerable danger that the grant of patents would “tie up” the use of such tools and thereby “inhibit future innovation premised upon them.” Id., at (slip op., at 17).

This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U. S. 303, 309 (1980) (Products of na- ture are not created, and “‘manifestations . . . of nature [are] free to all men and reserved exclusively to none’”). The rule against patents on naturally occurring things is not without limits, however, for “all inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas,” and “too broad an interpretation of this exclusionary principle could eviscerate patent law.” 566 U. S., at (slip op., at 2).

As we have recognized before, patent protection strikes a delicate balance between creating “incentives that lead to creation, invention, and discovery” and “imped[ing] the flow of information that might permit, indeed spur, in- vention.” Id., at _ (slip op., at 23). We must apply this well-established standard to determine whether Myr- iad’s patents claim any “new and useful . . . composition of matter,” §101, or instead claim naturally occurring phenomena. B It is undisputed that Myriad did not create or alter any of the genetic information encoded in the BRCA1 and

12 ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.

Opinion of the Court
BRCA2 genes. The location and order of the nucleotides existed in nature before Myriad found them. Nor did Myr- iad create or alter the genetic structure of DNA. In- stead, Myriad’s principal contribution was uncovering the precise location and genetic sequence of the BRCA1 and BRCA2 genes within chromosomes 17 and 13.

The question is whether this renders the genes patentable. Myriad recognizes that our decision in Chakrabarty is central to this inquiry. Brief for Respondents 14, 23–27. In Chakrabarty, scientists added four plasmids to a bacte- rium, which enabled it to break down various components of crude oil. 447 U. S., at 305, and n. 1. The Court held that the modified bacterium was patentable.

It explained that the patent claim was “not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or composition of matter—a product of hu- man ingenuity ‘having a distinctive name, character [and] use.’” Id., at 309–310 (quoting Hartranft v. Wiegmann, 121 U. S. 609, 615 (1887); alteration in original). The Chakrabarty bacterium was new “with markedly different characteristics from any found in nature,” 447 U. S., at 310, due to the additional plasmids and resultant “capac- ity for degrading oil.” Id., at 305, n. 1. In this case, by contrast, Myriad did not create anything.

To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention. Groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry. In Funk Broth- ers Seed Co. v. Kalo Inoculant Co., 333 U. S. 127 (1948), this Court considered a composition patent that claimed a mixture of naturally occurring strains of bacteria that helped leguminous plants take nitrogen from the air and fix it in the soil. Id., at 128–129. The ability of the bacte- ria to fix nitrogen was well known, and farmers commonly “inoculated” their crops with them to improve soil nitrogen

Cite as: 569 U. S. __ (2013) 13
Opinion of the Court levels. But farmers could not use the same inoculant for all crops, both because plants use different bacteria and because certain bacteria inhibit each other. Id., at 129– 130. Upon learning that several nitrogen-fixing bacteria did not inhibit each other, however, the patent applicant combined them into a single inoculant and obtained a patent. Id., at 130.

The Court held that the composition was not patent eligible because the patent holder did not alter the bacteria in any way. Id., at 132 (“There is no way in which we could call [the bacteria mixture a product of invention] unless we borrowed invention from the dis- covery of the natural principle itself ”). His patent claim thus fell squarely within the law of nature exception. So do Myriad’s.

Myriad found the location of the BRCA1 and BRCA2 genes, but that discovery, by itself, does not render the BRCA genes “new . . . composition[s] of matter,” §101, that are patent eligible. Indeed, Myriad’s patent descriptions highlight the problem with its claims.

For example, a section of the ’282 patent’s Detailed Description of the Invention indicates that Myriad found the location of a gene associated with increased risk of breast cancer and identified mutations of that gene that increase the risk.

See App. 748–749.4 In —————— 4The full relevant text of the Detailed Description of the Patent is as follows: “It is a discovery of the present invention that the BRCA1 locus which predisposes individuals to breast cancer and ovarian cancer, is a gene encoding a BRCA1 protein, which has been found to have no significant homology with known protein or DNA sequences. . . . It is a discovery of the present invention that mutations in the BRCA1 locus in the germline are indicative of a predisposition to breast cancer and ovarian cancer.

Finally, it is a discovery of the present invention that somatic mutations in the BRCA1 locus are also associated with breast cancer, ovarian cancer and other cancers, which represents an indicator of these cancers or of the prognosis of these cancers. The mutational events of the BRCA1 locus can involve deletions, insertions and point mutations.” App. 749.

14 ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.

Opinion of the Court
subsequent language Myriad explains that the location of the gene was unknown until Myriad found it among the approximately eight million nucleotide pairs contained in a subpart of chromosome 17. See Ibid.5 The ’473 and ’492 patents contain similar language as well. See id., at 854, 947.

Many of Myriad’s patent descriptions simply detail the “iterative process” of discovery by which Myriad nar- rowed the possible locations for the gene sequences that it sought.6 See, e.g., id., at 750. Myriad seeks to import these extensive research efforts into the §101 patent- eligibility inquiry. Brief for Respondents 8–10, 34.

But extensive effort alone is insufficient to satisfy the demands of §101. Nor are Myriad’s claims saved by the fact that isolating DNA from the human genome severs chemical bonds and thereby creates a nonnaturally occurring molecule. Myr- iad’s claims are simply not expressed in terms of chemical composition, nor do they rely in any way on the chemi- cal changes that result from the isolation of a particular section of DNA.

Instead, the claims understandably focus on the genetic information encoded in the BRCA1 and —————— Notwithstanding Myriad’s repeated use of the phrase “present invention,” it is clear from the text of the patent that the various discoveries are the “invention.” 5“Starting from a region on the long arm of human chromosome 17 of the human genome, 17q, which has a size estimated at about 8 million base pairs, a region which contains a genetic locus, BRCA1, which causes susceptibility to cancer, including breast and ovarian cancer, has been identified.” Ibid.

6Myriad first identified groups of relatives with a history of breast cancer (some of whom also had developed ovarian cancer); because these individuals were related, scientists knew that it was more likely that their diseases were the result of genetic predisposition rather than other factors.

Myriad compared sections of their chromosomes, looking for shared genetic abnormalities not found in the general population. It was that process which eventually enabled Myriad to determine where in the genetic sequence the BRCA1 and BRCA2 genes reside. See, e.g., id., at 749, 763–775.

Cite as: 569 U. S. __ (2013) 15
Opinion of the Court BRCA2 genes. If the patents depended upon the creation of a unique molecule, then a would-be infringer could arguably avoid at least Myriad’s patent claims on entire genes (such as claims 1 and 2 of the ’282 patent) by isolat- ing a DNA sequence that included both the BRCA1 or BRCA2 gene and one additional nucleotide pair.

Such a molecule would not be chemically identical to the molecule “invented” by Myriad. But Myriad obviously would resist that outcome because its claim is concerned primarily with the information contained in the genetic sequence, not with the specific chemical composition of a particular molecule.

Finally, Myriad argues that the PTO’s past practice of awarding gene patents is entitled to deference, citing J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred Int’l, Inc., 534 U. S. 124 (2001). See Brief for Respondents 35–39, 49–50. We disagree. J. E. M. held that new plant breeds were eligible for utility patents under §101 notwithstanding separate statutes providing special protections for plants, see 7 U. S. C. §2321 et seq. (Plant Variety Protection Act); 35 U. S. C. §§161–164 (Plant Patent Act of 1930).

After analyzing the text and structure of the relevant statutes, the Court mentioned that the Board of Patent Appeals and Interferences had determined that new plant breeds were patent eligible under §101 and that Congress had recog- nized and endorsed that position in a subsequent Patent Act amendment. 534 U. S., at 144–145 (citing In re Hib- berd, 227 USPQ 443 (1985) and 35 U. S. C. §119(f)).

In this case, however, Congress has not endorsed the views of the PTO in subsequent legislation. While Myriad relies on Judge Moore’s view that Congress endorsed the PTO’s position in a single sentence in the Consolidated Appro- priations Act of 2004, see Brief for Respondents 31, n. 8; 689 F. 3d, at 1346, that Act does not even mention genes, much less isolated DNA. §634, 118 Stat. 101 (“None of the funds appropriated or otherwise made available under this

16 ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.

Opinion of the Court
Act may be used to issue patents on claims directed to or encompassing a human organism”). Further undercutting the PTO’s practice, the United States argued in the Federal Circuit and in this Court that isolated DNA was not patent eligible under §101, Brief for United States as Amicus Curiae 20–33, and that the PTO’s practice was not “a sufficient reason to hold that isolated DNA is patent-eligible.” Id., at 26. See also id., at 28–29.

These concessions weigh against deferring to the PTO’s determination.7 C cDNA does not present the same obstacles to patentabil- ity as naturally occurring, isolated DNA segments. As already explained, creation of a cDNA sequence from mRNA results in an exons-only molecule that is not natu- rally occurring.8 Petitioners concede that cDNA differs from natural DNA in that “the non-coding regions have —————— 7Myriad also argues that we should uphold its patents so as not to disturb the reliance interests of patent holders like itself.

Brief for Respondents 38–39. Concerns about reliance interests arising from PTO determinations, insofar as they are relevant, are better directed to Congress. See Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U. S. , (2012) (slip op., at 22–24). 8Some viruses rely on an enzyme called reverse transcriptase to re- produce by copying RNA into cDNA.

In rare instances, a side effect of a viral infection of a cell can be the random incorporation of fragments of the resulting cDNA, known as a pseudogene, into the genome. Such pseudogenes serve no purpose; they are not expressed in protein creation because they lack genetic sequences to direct protein expres- sion. See J. Watson et al., Molecular Biology of the Gene 142, 144, fig. 7–5 (6th ed. 2008).

Perhaps not surprisingly, given pseudogenes’ apparently random origins, petitioners “have failed to demonstrate that the pseudogene consists of the same sequence as the BRCA1 cDNA.” Association for Molecular Pathology v. United States Patent and Trademark Office, 689 F. 3d 1303, 1356, n. 5 (CA Fed. 2012). The possibility that an unusual and rare phenomenon might randomly create a molecule similar to one created synthetically through human ingenuity does not render a composition of matter nonpatentable.

Cite as: 569 U. S. __ (2013) 17
Opinion of the Court been removed.” Brief for Petitioners 49. They neverthe- less argue that cDNA is not patent eligible because “[t]he nucleotide sequence of cDNA is dictated by nature, not by the lab technician.” Id., at 51. That may be so, but the lab technician unquestionably creates something new when cDNA is made. cDNA retains the naturally occurring exons of DNA, but it is distinct from the DNA from which it was derived.

As a result, cDNA is not a “product of nature” and is patent eligible under §101, except insofar as very short series of DNA may have no intervening introns to remove when creating cDNA. In that situation, a short strand of cDNA may be indistinguishable from natural DNA.9 III It is important to note what is not implicated by this decision.

First, there are no method claims before this Court. Had Myriad created an innovative method of manipulating genes while searching for the BRCA1 and BRCA2 genes, it could possibly have sought a method pat- ent. But the processes used by Myriad to isolate DNA were well understood by geneticists at the time of Myriad’s patents “were well understood, widely used, and fairly uniform insofar as any scientist engaged in the search for a gene would likely have utilized a similar approach,” 702 F. Supp. 2d, at 202–203, and are not at issue in this case.

Similarly, this case does not involve patents on new applications of knowledge about the BRCA1 and BRCA2 genes. Judge Bryson aptly noted that, “[a]s the first party with knowledge of the [BRCA1 and BRCA2] sequences, Myriad was in an excellent position to claim applications of that knowledge. Many of its unchallenged claims are —————— 9We express no opinion whether cDNA satisfies the other statutory requirements of patentability. See, e.g., 35 U. S. C. §§102, 103, and 112; Brief for United States as Amicus Curiae 19, n. 5.

18 ASSOCIATION FOR MOLECULAR PATHOLOGY v.
MYRIAD GENETICS, INC.

Opinion of the Court
limited to such applications.” 689 F. 3d, at 1349. Nor do we consider the patentability of DNA in which the order of the naturally occurring nucleotides has been altered. Scientific alteration of the genetic code presents a different inquiry, and we express no opinion about the application of §101 to such endeavors.

We merely hold that genes and the information they encode are not patent eligible under §101 simply because they have been isolated from the surrounding genetic material. * * * For the foregoing reasons, the judgment of the Federal Circuit is affirmed in part and reversed in part.
It is so ordered.

SCALIA, J., concurring

Cite as: 569 U. S. __ (2013) 1
Opinion of SCALIA, J. SUPREME COURT OF THE UNITED STATES
No. 12–398
ASSOCIATION FOR MOLECULAR PATHOLOGY,
ET AL., PETITIONERS v. MYRIAD
GENETICS, INC., ET AL.
ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF
APPEALS FOR THE FEDERAL CIRCUIT
[June 13, 2013]

JUSTICE SCALIA, concurring in part and concurring in the judgment. I join the judgment of the Court, and all of its opinion except Part I–A and some portions of the rest of the opin- ion going into fine details of molecular biology. I am un- able to affirm those details on my own knowledge or even my own belief.

It suffices for me to affirm, having studied the opinions below and the expert briefs presented here, that the portion of DNA isolated from its natural state sought to be patented is identical to that portion of the DNA in its natural state; and that complementary DNA (cDNA) is a synthetic creation not normally present in nature.

Peace, Love & Blessings To All!

Oliver

Orders of Magnitude Higher Deaths in the Vaccinated’: Israel’s Vaccine Data Reveals a Frightening Picture

The grand total is 43781 COVID patients who got the first or the second vaccine dose. Among the total of 660 deaths, 546 got only the first dose.

Unrelated To The Covid-19 Vaccination Death Toll In Israel, 246 Fully Vaccinated Michigan Residents Get Covid-19 And 3 Died

https://nypost.com/2021/04/06/246-fully-vaccinated-michigan-residents-get-covid-3-die-report/

Orders Of Magnitude Increases In Covid-19 Vaccine Death Rates

VPosted on: Wednesday, March 3rd 2021 at 6:45 am Posted By: GMI Reporter This article is copyrighted by GreenMedInfo LLC, 2021
Visit our Re-post guidelines

Republished from Nakim.org

In the article republished from Nakim.org, research is presented indicating orders of magnitude increases in death rates during the 5-week long vaccination process analyzed in Israel, as compared to the unvaccinated and those after completing the vaccination process.

On February 11 2021 Ynet (the most known Israeli News website) published a confused and confusing article entitled “Vaccination efficiency data in Israel, and its rapid effects on the young”.

Our reanalyses of these data explain why during the massive vaccination project initiated mid-December 2020 during a confinement, daily new confirmed COVID-19 cases failed to decrease as they do during confinements, and, more importantly, why numbers of serious, critical and death cases increased during that period that covered at least one month.

From mid-December to mid-February (two months), 2337 among all Israeli 5351 official COVID-deaths occurred. Our analyses indicate orders of magnitude increases in deaths rates during the 5-week long vaccination process, as compared to the unvaccinated and those after completing the vaccination process. Presumably, asymptomatic cases before vaccination, and those infected shortly after the 1st dose, tend to develop graver symptoms than those unvaccinated.

The Ynet article is organized in an exciting way and uses data provided in an erroneous way by the Ministry of Health. It is unclear whether this was intentional to prove the vaccine’s efficiency or if this was done erroneously because the provided data were misunderstood. Note that in Israel, all vaccines are from Pfizer.

We bring a very important example from the article, in relation to the table provided by the Ministry of Health. As per the text “However, 546 among the dead were such that were not at all vaccinated or got the first vaccination dose within two weeks before their death” differs from the table.

This is clearly unfounded because all data presented in the table and provided below describe only COVID-19 patients that got at least the first vaccination dose. This is clear from examining the table. The grand total is 43781 COVID patients who got the first or the second vaccine dose. Among the total of 660 deaths, 546 got only the first dose.

The Data In The Table, Rather Than Indicating The Vaccine Efficiency, Indicate The Covid-19 Vaccine Adverse Effects

For that purpose we need first to understand that the provided table describes the state of COVID-19 patients that got the first or the second vaccine dose at given dates, as started in the article “…emerges from the data that among 856 patients above 60 years in serious state hospitalized at this time…” we assume that the article published February 11 reflects the situation in hospitals the previous day, hence February 10 2021, or February 11 2021.

Serious Active Cases

On February 10, the number of serious active cases was 1056 according to the control panel of the Ministry of Health, see photo below.

This surprisingly shows that most serious hospitalized cases on February 10 or at a near date were in fact vaccinated with the first dose or up to two weeks after the second dose. See the table of the vaccinated patients showing 1031 serious and 220 critical cases at the time the table was done. This matches the article in hebrew from February 1st 2021 “Can one show that the vaccine from Pfizer is today’s major cause for high death rates in Israel and the world?”.

However, this is not the last surprise we get from examining the data from the Ministry of Health. We can substract the number of people with the first vaccine dose on January 19 2021 from that on February 10 2021. During these 21 days, 1331881 Israeli citizens got the first dose. The table shows that 568 among these died, hence 0.042% and that 39047 among them became a COVID-19 case, hence 2.9 %. For the 2nd dose we focus on data specific to two weeks after the 2nd vaccination according to the table.

From January 26 to February 10 2021 909102 Israeli citizens got the 2nd vaccine dose. Among these according to the table, 92 died, 0.01%. Hence, during the 5 weeks since the first dose at least 0.05% of first dose recipients died. This death rate relates mainly to a relatively young population whose vaccination stated on January 19, a period during which most vaccinated were below 65. In order to estimate the death rate of those above 65 which were mostly vaccinated before that period we use data reported by the USA-based VAERS,

There we found, see article in english, that the ratio of deaths by those above 65 vs those below 65 is about 4.42 (155/35). Hence the death rate of those above 65 between the first and the second vaccination dose should be until January 19 0.042 (the death rate of those below 65) multiplied by 4.42, resulting in 0.186%, which is close to the 0.2% reported by the Ministry of Health on January 21 2021.

This value of 0.2 % death has been mysteriously modified later on by the Ministry of Health and was switched to 0.005 without any explanation, see article in hebrew. Above considerations show that the death rate data provided first were correct, the updated death rate data might have been intended to suggest lower death rates among the elderly.

The exposures do not end here.
The number of COVID-19 deaths among the vaccinated since the start of the vaccination action seems to explain the increased death rates from COVID-19 observed since December 2020. For that purpose, we calculate the products of the number of vaccinated people above age 65 by 0.2 and the number of vaccinated people below 65 by 0.04. This shows that most COVID-19 deaths in that period are for vaccinated people, as shows the table provided by the Ministry of health at the beginning of February.

During the vaccination action from mid-December until mid-February, 2337 among all 5351 COVID-19 deaths reported for Israel occurred, 43.7%. Among these, since January 19, 1271 COVID-19 deaths were reported for Israel.The table provided by the Ministry of Health on February 10 states 660 COVID-19 deaths among the vaccinated, 51.9% of the deaths for that period.

Only 1.3 million Israeli, among 8 million (about 1 in 8, 12.5%), were vaccinated during that period. Accordingly, vaccination promotes deaths because 51.9% of deaths during that period are for the 12.5% vaccinated in that period. In addition the serious and critical cases during that period is more than the reported serious cases, the adverse effect of the vaccination process is most likely worse than what appears from the data at hand.

The horror continues. The deaths among those vaccinated should be added to the numerous AVC and cardiac events reported just after vaccination that are not included among COVID-19 deaths which about double the deaths among those vaccinated, whose numbers remain unknown and which we will try to find in the coming days. At this point we state that vaccinations caused more deaths than the coronavirus would have during the same period.

Among those vaccinated and above 65, 0.2% of those vaccinated died during the 3-week period between doses, hence about 200 among 100000 vaccinated. This is to be compared to the 4.91 dead among 100000 dying from COVID-19 without vaccination, see below. This should not be confused with the COVID-19 0.279 deaths among 100000 reported for those who completed the vaccination process, meaning 2 weeks after the second dose, see below table from the Ynet article.

Death Per Age Group

death per age translated — **Death Per Age Translated**

This scary picture also extends to those below 65, among which, for the 5 weeks during the complete vaccination process 0.05%, meaning 50 among 100000, died. This is to be compared to the 0.19 per 100000 dying from COVID-19 and that are not vaccinated in that age group, as per the above table. Hence the death rate of this age group increased by 260 during this 5-week period of the vaccination process, as compared to their natural COVID-19 death rate.

A simple way to pass these points across relate to the monthly COVID-19 deaths rates since the start of the pandemic and until mid-December, 3014 deaths, hence 3014/9 = 334.9 deaths per month. Monthly death rates since mid-December are 2337/2 = 1168.5 deaths per month, hence 3.5 times greater.

We conclude that the Pfizer vaccines, for the elderly, killed during the 5-week vaccination period about 40 times more people than the disease itself would have killed, and about 260 times more people than the disease among the younger age class. We stress that this is in order to produce a green passport valid at most 6 months, and promote Pfizer sales.

These estimated numbers of deaths from the vaccine are probably much lower than actual numbers as it accounts only for those defined as COVID-19 deaths for that short time period and does not include AVC and cardiac (and other) events resulting from the inflammatory reactions in tens of reports documented on the NAKIM site, which themselves are only the iceberg’s tip, see here.

This does not account for long-term complications described in a criminal complaint filed in December 2020 in France and which was translated to english, see here.
Looking back, this explains why the serious COVID-19 cases increased as vaccination started, and why cases started to decline when vaccination was opened to the young and continue to decline as the vaccination national campaign is losing its momentum.

We hope that this massacre will not include those below 13, as these have an increased adverse reaction rate, including death, to vaccines as shown by multi-decennial data from the VAERS reports in the USA.

We summarise that the pandemic may be predicted for the coming weeks. The decrease in vaccinations and in vaccination age will cause a decrease in serious cases, mainly not because of the protection by the vaccine, but because fewer people will die from the vaccine and other adverse vaccine reactions.

This will be temporary as in a few months we expect to face mid- and long-term adverse effects of the vaccination as ADE (Antibody-dependent Enhancement) and the vaccination-resistant mutants selected by the vaccines. But this should occur after the soon coming elections and the (survivor) voters won’t have another opportunity to express their disappointment at the voting poll.

Thanks to Dr Hervé Seligmann for his huge support on data analysis.

Haim Yativ

There is a lot of information coming out from brave people putting their lives and livelihoods on the line to get the truth out! Join the true heroes and stand up for what is right. Like these two heroes, Dr. Philip McMillan and Dr Geert Vanden Bosshe

Peace, Love & Blessings To All!

Oliver

Sources:

GreenMedInfo.com

Nakim.org

COVID-19 Shot Or Vaccine

It’s a very bad situation here. They make people wear an anklet. It’s absolutely insane! But in the meantime we just keep fighting ..
Fight as much as we can. So we need everyone’s help! Because what happens here is going to happen everywhere …
So we fight for ourselves and we fight for the whole world, but we need help. We need every help possible! All hands on deck.

Say What You Will…I’m Saying This:

Calling someone an Anti-Vaxxer and saying that they’re bad, is like calling Neighborhood Watch groups bad. We, the people who oppose vaccinations research what goes in the vaccinations we oppose. Like in this post about Carrie Liebich when she called poison control about the ingredients she got from the package insert of a vaccination. The Poison Control person was FLOORED when she told him where she got the ingredient list.

We are not against vaccinations, I’m pretty confident that I can speak for all that are dubbed “Anti-Vaxxer”, that we are Anti-Crimes Against Humanity, that we are Anti-Big Pharma, that we are Anti-Greed. Personally, I would take the COVID-19 Shot, if it were in fact a vaccination, but it’s most DEFINITELY NOT!

We’ve been sold a bill of goods. It IS Medical Experimentation. If you’ve received this SHOT, you’ve been injected with Nano-Technology, Nano-Bots that are going to alter your DNA.

This is part of a World-Wide wake-up call. Ilana is right, we have an incredible opportunity to finally bridge the gap between all cultures, to remove the wedges that have been driven between all of us at every possible moment.

If we stand up and say that’s it, ENOUGH IS ENOUGH!! They will crumble!

Read the transcript of the interview below and listen to the soundbite of Ilana Rachel Daniel talking about what’s happening in Israel…she starts crying…very emotional. You can watch the interview by clicking the link below.

I’m going to add it here because YouTube may remove it soon. I just wanted to get this posted quickly.

Israel’s COVID-19 Vaccine Or mRNA Experimentation

Ilana Rachel Daniel came with an emotional outcry for help from Jerusalem, the capital of Israel. At record speed, the government is trying to vaccinate the entire population – including pregnant women and small children – against the corona virus. “Civil rights are put aside and people can only participate in society again after vaccination,” told Ilana to Flavio Pasquino in the BLCKBX studio via a live stream connection, who tracked down Ilana after an – even – more emotional audio clip on Telegram.

Ilana Rachel Daniel talks about the Green Pass, the Freedom Bracelet, the mRNA vaccine and human rights violations. “Currently reminiscent of the Holocaust,” said the Jewess who emigrated from the US to Jerusalem 30 years ago. Ilana Rachel Daniel is active in Jerusalem as a health advisor and information officer for a new political party (Rappeh) that is heavily opposed by the regime. Opening a banc account is not possible and members of the party are also thwarted in their daily lives.

Ilana Rachel Daniel Crying As She Warns The World

Ilana Rachel Daniel Crying About Israeli COVID-19 Vaccine Program

Full Transcript From The Ilana Rachel Daniel Interview on BLCKBX

Ilana Rachel Daniel: It’s called the green passport. We’re not told to wear it, but what they’ve done is that they have essentially created a second-class citizenry overnight. A real medical apartheid that forbids healthy, law-abiding, tax-paying citizens from visiting cultural places, if they don’t participate in this experiment. It’s that simple. We have been literally told that there are people who have been kicked out of their choir, from their pools, from their gyms.

I don’t know who will hear the message we’re saying. I don’t know what’s going to happen.

I know there is no other option than every fiber of energy and strength to combat this, as there is no other option. There is everything to lose and everything to win, and I never really think it has been so simple.

I simply believe that we are privileged to have this truth. There is a truth that I think is a common denominator. Between all these different people, different countries, different languages, and we all see and hear a very clear truth.

And I think that truth is an absolute gift. But it is an obligation.

And it is not given to us to sit at home and with this apathy and hope for the best. We all need to come together because this is really how we win. Making these connections between us country after country is the only thing that these governments fear. They have it most of all, they have the wealth of empires behind them. But when the people realize that we are the many and they are the small group, they have nothing.

They have nothing and I can never give up hope that we will build this strength and take back our lives.

Because I’ve said before, I feel like the ball is in the air. It’s like this volleyball and it’s a matter of who hits it. We are not going back. There is no way back.

There has been progress and we have a great opportunity. And we have a great opportunity to come together as people. Without the divisions caused by religion, for example. They push us to make this complete reset. Actually we will just be people in such a beautiful way.

As painful as these divorces they made. We can really come together in a way that is how it is meant to be. That’s my opinion. Ilana Rachel welcome to the BLCKBX studio. Yesterday I listened to a disruptive audio file from you all the way from Jerusalem.

Transcript Of The Soundbite Above

It’s a very bad situation here. They make people wear an anklet. It’s absolutely insane! But in the meantime we just keep fighting ..Fight as much as we can. So we need everyone’s help! Because what happens here is going to happen everywhere …So we fight for ourselves and we fight for the whole world, but we need help. We need every help possible! All hands on deck.

Back To The Interview On The BLCKBX YouTube Channel

Flavio Pasquino: It gave me goosebumps and that’s why me wanted to talk to you directly, to hear from your side what is happening in Israel. What is going on, in short, I do not know if there is a short version, but that our Prime Minister Benjamin Netanyahu has taken the initiative to register us without our informed consent to be the test subjects for Pfizer’s experimental technology.

And they do, with almost brute force.

Using coercion methods such as threatening people with their livelihoods, threatening young children as 16-year-olds. that they cannot take an entrance exam. The rollout of this is very ..

. This plan is observable in several countries. In some countries they give you the option to come and sign up, but there is no option here. You really have to come and do it. It’s as if the scientific evidence is established, even if it doesn’t even exist.

There is already great governmental and social pressure to hurry this up. This experiment. In Israel they don’t even talk about it being an experiment. While the rest of the world is fully aware. That’s exactly what this is.

Flavio Pasquino: Are you saying that vaccines are currently mandatory in Israel?

Ilana Rachel Daniel: Vaccines are not mandatory in Israel, but this covid-19 shot is … Well, it’s just kind of mandatory.

They say it is not mandatory and not enforced, however the reality on the ground is that people are losing their jobs. For example if they work in healthcare, or if they have some kind of job within the healthcare sector. There are many different places where people are told you must be vaccinated or else you will lose your job.

Flavio Pasquino:You told me about it earlier in this audio file people who wear some sort of batch on their wrist. The free pass or something? What is all that?

Ilana Rachel Daniel: It’s called the green passport.

We were not told to wear it, but what they did is that they have essentially created a second-class citizenry overnight. A true medical apartheid that denies healthy, law-abiding, tax-paying citizens access to their places in society if they do not participate in this experiment. It’s that simple.

We have been literally told that there are people who have been kicked out of their choir, from their pools, from their gyms.

Like I said, there are incredible social pressures and divisions between them families and this illusion of science that you don’t participate in, so that’s why you become seen as a virus carrier, threatening the rest of us. Even if of course there are simply no existing safety studies. So it’s really all in the name of science, but they’re actually all doing something based on an illusion.

Flavio Pasquino: What happens to people from abroad who enter Israel? For example with an airplane? What must they do to rejoin society?

Ilana Rachel Daniel: One of the worst scenes of what is happening can be seen at the airport. This morning I read someone’s personal story about coming home. His father happens to be a survivor, a Holocaust survivor, and he literally felt like he was in a roster.

It was very clear: those who are vaccinated go to one side and those who are not vaccinated go to the other side and are forced into these filthy hotels where they have to stay.

There they will all have to be swabbed with a PCR test. Then there is also the option, again change the rules from morning to evening, but apparently for some there is also an option to wear a security, a real one security ankle bracelet, as if they were a prisoner in their own home, and you have to pay 2,000 shekels (approx. € 500) for the privilege of doing this. This is what they do with their own citizens who have the audacity to travel.

Flavio Pasquino: So what I understand is that the security ankle strap is actually a way to have a liberal home quarantine?

Ilana Rachel Daniel: Yes, that’s the liberal version, correct, correct.

What we see here, those of us in Israel, we understand that we are used as a model for the rest of the world, because of the larger plans of this one injection for the rest of the world and for the larger plans of those governments want to increase this imposed control.

There is a feeling that it has to work. They don’t give us a choice because we are the model to show everyone how wonderful this new version of life is. So we are dealing with extraordinary powers. We know how the bottomless wealth of the pharmaceutical companies.

We know the governments all over the world. But this … The year of extreme implementations and policies .

.. it all culminates here in Israel, currently, with the rollout of this program. So, like I said, while it is in other countries is still a choice. Here, in my opinion, is the only reason that they are not physically because there would be too much public outrage, but they do everything just on the edge.

It’s the same old story, it’s the different, it’s this version it is.

Do you understand? It’s the idea that the other is going to bring danger to my, you know, my safe place. And those have become the people who are not willing to participate in this experiment.

Flavio Pasquino: Is there any resistance in Israel to these events? I mean, if you look at it in one historical and also religious perspective, you could say after what happened to the Jews through history and they finally have their promised land. It’s kind of cynical what is happening to the Jews in Israel now.

Ilana Rachel Daniel: It can’t be, you know, I don’t know whether it was planned to start here from the beginning.

I know there are logical reasons why this program has been rolled out here in Israel. But that our people went through the Holocoust and you have some elderly people who are Holocaust survivors are now being tested in their homeland, in our refuge, again by the same company, just with a different name.

You really couldn’t have tailored a bigger betrayal. Because the truth of the matter is this should be our hideout and we’re standing now in the midst of a danger that no one can describe. We know the immediate health, We know a lot of the immediate health problems, but the fertility problems .

.. We’ve rolled out a program never took into account the fact that the only group of people who were ever at risk of dying …

with the exception of this virus who was 65 years of age and older and those with co-morbidities. They’ve instilled such a sense of fear during the rollout of this experimental program that they’ve even run it on pregnant women. Pressuring children from the age of 16, women and pregnant women through literal radio messages Come .. come .

. and get vaccinated! You save your baby! And the night before they roll out a program. It’s this, for the first time in the year.

They release news reports that say: “Oh we suddenly have 30 pregnant women in critical condition in the hospital.” It’s so rough and obvious and people believe it! They just seem to believe it. They seem to forget not only basic science, but everything. Their experience itself .

.. The only saving grace and whole virus was that the children were spared and instead, We pretend that a pregnant woman has to take an mRNA technology into her body …

I lived in Israel for almost 24 years and I could never, never could have imagined that we would do these things … I never could have imagined and the thing is we know it is no secret. There is a contract.

There is a real physical contract between them Pfizer and our government. We have only seen an edited version. What we know is that there is a penalty clause. They have to now, the government of Israel is acting incredibly desperate, because they have some sort of quota of people they have to reach and inject. I don’t know what this penalty clause means.

Obviously, it must be something more terrible than risking the health of your own the generations to come of all your people. But we know that that exists and we know that they are in a situation where they feel a lot of pressure. So they act silly and more extreme. For example, they send messages in which you offer people a slice of pizza to get your injection.

it’s just a twilight zone and what’s more painful isn’t just how extreme it is because it is so obvious to anyone who is willing to give in, but there are so many people out there still have faith in our government for a variety of reasons.

And pretend all this could still be about a virus. We are boiled alive in this pot and pretend it’s not that hot …

It is very painful to see the people we love and respect as our neighbors and our relatives still pretend to be what’s really going on.

Flavio Pasquino: Ilana in the Netherlands we are going to meet new elections very soon and there is a politician who has a home in Israel. Her name is Sigrid Kaag, she worked for the united nations and she actually sets Israel as an example in the Netherlands. And in the news, she says we should look at the success Israel has already achieved. What would you like to say to her?

Ilana Rachel Daniel: I would like to tell her that the data is not being collected. We are not giving these people, these Israeli citizens, zero informed consent, no opportunity to make a risk benefit analysis. There is no way for the people to understand what they are signing for. And not only that. What happens is they get an injection and within 15 minutes standing outside again. Without paperwork.

There is no list of the side effects to look out for. There is no number to call.The data is not reported. There have been a number of attempts by citizens to register what our Ministry of Health does not register. Only the most extreme things are in the news and they have even stopped doing so.

Then the first They have cases of bell’s palsy and the first elderly fell dead within hours of heart failure the next day the headlines changes. Oh there is no relationship. There was no relationship to the injection they received. I personally know people who work in medical facilities who have seen a 40-year-old die of heart failure two days after the injection.

And they are not allowed to say it.

They can’t say it had anything to do with this vaccine! It’s an absolute threat. If you get shot in the head, but you test positive for covid, you died of covid. But if you die of heart failure within two weeks after getting the injection, it has no correlation. We live in a dream world and we deserve better.

We all deserve better. And it’s not, it’s definitely not accurate, it’s not scientific and we know the whole idea to call this a vaccine, even though we know it’s actually an experimental gene treatment. Using the word vaccine is using that part of your brain that doesn’t think at all. That has this knee-jerk reaction because we know that vaccines are automatically considered as safe and monitored / tested for decades.

Over and over again, it is this idea that people have about it.

So they use the word “vaccine,” and it doesn’t matter to name the flaws in that story but what using them now, is so full of uncertainties. It is insulting to have to take this all the time. The point is, we know that every vaccine takes at least 10 years. The technology used has been around for decades and it has never left the laboratory because it causes problems. It never got past animal testing.

Ferrets, rabbits, cats, monkeys all died during the animal experiments. And now we’re sticking it in the entire Israeli population. It never has well tested apart from the only time MRNA has been used in the most extreme cases. None of the actual treatments that we have been given all year round. And they are not given so that we can use this technology.

Flavio Pasquino: Let’s go back to human rights. What is actually happening to society in Israel? Do you still feel like you live in a free and open society?

Ilana Rachel Daniel: No absolutely not. I think you hear people talking about where can we go? People are terrified of what’s to come.

From one day to the next. For what will be for our children in the future. There the division is so extreme and are so unreasonable. And I think even people who signed up and took the vaccine start to see that something is going on because it is so extreme and the government so desperate.

But you now know that if you walk out without a mask. It’s the same story you hear everywhere. You have people who are willing to yell at you in the street for not wearing a mask. And that’s just the beginning. They have managed to this story that you are a walking disease risk if you walk into someone’s shop, for example without this injection, which of course has no chance of stopping the transmission. It’s not what it was made for.

Flavio Pasquino: I understood that you also run a political party in Israel. Are you succeeding?

Ilana Rachel Daniel: We are making incredible progress, despite full censorship. They have taken our Facebook page from the internet with 60,000 followers.

And they have revoked the medical license from the head of our party. They do everything they can to delegitimize us, but of course they fail. It just makes it clearer that small parties are in Israel have historically faced a tremendous challenge. They don’t even allow us to open a bank account to receive donations. They do everything they can to stop us because we are the only party to go against the story that puts them in danger.

These left-right answers, they don’t care. We are the only people who stand up and say this is unacceptable. This is absurd, this is unreasonable. You know the Israelis have been in lockdown for 5 months. Being locked up in our small apartments for five months.

Israel is a very small country We do not have large gardens. It’s absurd. Children with masks on, slumped for endless zoom conversations. You really have a people like that is so weakened. Do you know how many people there are that the government is telling you to take this shot!

Oh yeah, that’s fine.

It doesn’t feel right, but okay, I’m going to do it because let me get out of this now. They tell me this is a solution and even though my gut tells me it’s not right. Do you know how many people will take the extra steps to find out? Not enough.

Flavio Pasquino: How do you see the future for Israel in the next four or five years? What do you think will happen?

Ilana Rachel Daniel: So I’ll tell you, I find …

I have absolutely no idea … The future has never been more opaque. I think that’s true for so many of us throughout world right now.

And I feel that, you know, not to be clichéd, but dissipate a little bit of light a lot of darkness and it’s just a step, a step I take leads me to the next step, leads us to the next step. I don’t know what’s going to happen. Even these elections are supposed to happen on March 23. That is still a lifetime away in the world we now live in. I don’t know who will hear the message we say.

I don’t know what’s going to happen. I know that there is no other option but to give every fiber of energy and strength to combat this, because there is no other option. There is everything to lose and everything to gain. I guess it has never been easier in some ways ..

. And I believe that That it … I just believe that.

We are privileged to have this truth.

There is truth, which I think is a common denominator against all these different people, different countries, different languages and we all see and speak a very clear truth, and I think that truth is an absolute gift. But it is an obligation and it was not given to us to just sit at home and with this apathy and hope for the best. We all need to come together because this is really how we win. Making these connections between us country after country.

That is the only thing that these governments fear. They have the wealth of empires behind them, but when the people realize that we are the many and that they are just a small group, they have nothing. They have nothing and I can never give up hope that we will build this strength. And take back our lives because I said before that I feel like the ball is in the air. It’s like this volleyball and it’s a matter of who hits.

We are not going back to the old normal. There is no way back. There has been progress and we have a great opportunity. We have a great opportunity to come together as people without the issues of religion.

They’re pushing us to make this complete reset.

We can really just be human beings in such a beautiful way, as painful as these divisions that they’ve made. We can really get together the way it is meant to be … that’s my opinion!

Flavio Pasquino: Thank you Ilana for your courage, for your honesty. I think what you are saying is absolutely correct. And it is very disturbing to hear what is happening in Israel. We see about the same things happening in Europe and in the Netherlands. For me it seems like a nightmare that we are still in and I hope every day that we wake up from this from this terrible dream.

That it’s not the truth, but it is. So I want to thank you for this conversation from Jerusalem. I’ve never spoken to anyone from Jerusalem, out of it promised land, and it shouldn’t be. Thank you, Ilana!

Ilana Rachel Daniel: Thank you Flavio, thank you!

Flavio Pasquino: We hope this video from Jerusalem will go viral worldwide, so we end this video with a request. Please share this video with as many people as possible and thank you for watching!

Peace, Love & Blessing To Us All!
Oliver